Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Dakota Wealth Management

Dakota Wealth Management lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,140 shares of the medical research company’s stock after buying an additional 2,245 shares during the quarter. Dakota Wealth Management’s holdings in Amgen were worth $8,393,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Cullen Investment Group LTD. purchased a new stake in Amgen during the 4th quarter worth about $2,503,000. BOK Financial Private Wealth Inc. purchased a new stake in Amgen during the 4th quarter worth about $29,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors increased its position in Amgen by 1.2% during the 4th quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 11,515 shares of the medical research company’s stock worth $3,317,000 after purchasing an additional 141 shares in the last quarter. Carnegie Capital Asset Management LLC increased its position in Amgen by 4.7% during the 4th quarter. Carnegie Capital Asset Management LLC now owns 87,053 shares of the medical research company’s stock worth $25,073,000 after purchasing an additional 3,893 shares in the last quarter. Finally, Vontobel Holding Ltd. increased its position in Amgen by 13.7% during the 4th quarter. Vontobel Holding Ltd. now owns 265,752 shares of the medical research company’s stock worth $76,542,000 after purchasing an additional 32,085 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on AMGN shares. Royal Bank of Canada restated an “outperform” rating and issued a $329.00 price target on shares of Amgen in a report on Wednesday, April 3rd. Oppenheimer restated an “outperform” rating and issued a $350.00 price target on shares of Amgen in a report on Thursday, February 1st. Morgan Stanley lowered their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. SVB Leerink cut Amgen from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $324.00 to $318.00 in a report on Wednesday, February 7th. Finally, Raymond James began coverage on Amgen in a report on Thursday, March 28th. They issued a “market perform” rating for the company. Ten analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $295.30.

Amgen Stock Up 0.2 %

Shares of AMGN traded up $0.53 during trading on Monday, reaching $267.81. The company’s stock had a trading volume of 361,090 shares, compared to its average volume of 2,863,609. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The company has a market cap of $143.52 billion, a price-to-earnings ratio of 21.40, a P/E/G ratio of 2.53 and a beta of 0.58. The company has a fifty day moving average of $280.76 and a two-hundred day moving average of $281.55.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the business earned $4.09 EPS. On average, sell-side analysts predict that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.36%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.